

4th floor Ropemaker Place 25 Ropemaker Street London EC2Y 9LY United Kingdom

tel +44 20 7260 2000 fax +44 20 7260 2001 www.markit.com

Markit Commentary

October 22nd 2015

Valeant bonds facing crisis of confidence

Valeant bonds crashed yesterday as a short selling research firm alleged it misrepresented sales; this has pushed the entire healthcare high yield sector in.

- CDS spread jumped to an all-time high of 657bps
- Valeant 2021 bonds trading at 88 cents to the dollar, with current yield 6.8% more than treasuries
- The Markit iBoxx USD Liquid High Yield Health Care index lost 1.5% yesterday

Yesterday's shock market development saw short selling research firm Citron allege that controversial biotech firm Valeant Pharmaceutical inflated its sales figures by selling to "phantom captive pharmacies" in a plot reminiscent of the Enron scandal of over a decade ago. These allegations were taken to heart by the market as evidenced by Valeant's shares slumping by over 40% in Valeant session lows. While shares rebounded somewhat in late trading to trim half their losses, the crash means that Valeant shares have lost over half their value from their highs in early August.


While most of the attention yesterday was focused on the firm's floundering share price, the fixed income market was also busy digesting the news and Valeant bonds are now facing the largest amount of investor scepticism on record.

This scepticism is evidenced by the firm's CDS spread, which is trading 177bps wider. Despite the spate of attention in recent weeks, stemming from allegations of price gouging, Valeant's CDS is still relatively illiquid. Only two brokers contributed prices, which earns it the second worst liquidity score on the Markit CDS liquidity scale.

Valeant's bonds have been much more liquid over the last few weeks as the 5.625% 2021 note has the most liquid note according to Markit's evaluated bond pricing service.

That note traded eight cents to the dollar cheaper yesterday to 88. That price crash

means that investors are now requiring 6.8% of extra yield over benchmark US treasuries to hold the note, up from 3.5% earlier in the summer. VALPIT 5.625 12/01/21



Valeant is a relatively leveraged player with \$18bn of long term debt on its balance sheet so the firm will need to placate the bond market in order for the equity portion of its balance sheet to recover. Failure to do so could see the firm enter a pattern similar to the one seen in Glencore last month.


Impact on sector

Valeant's indebtedness means that it is the eight largest constituent of the Markit iBoxx USD Liquid High Yield Health Care index. That index lost 1.5% yesterday to see its yield push past the 5.95% mark. The index spread is now 417bps, 8bps less than the recent seen just after highs Hillary Clinton



announced that she was looking to crack down on what she viewed as price gouging within the industry.

High Yield Healthcare Bonds



Simon Colvin

Analyst

Markit

Tel: +44 207 260 7614

Email: simon.colvin@markit.com

For further information, please visit www.markit.com

The intellectual property rights to this report provided herein is owned by Markit Group limited. Any unauthorised use, including but not limited to copying, distributing, transmitting or otherwise of any data appearing is not permitted without Markit's prior consent. Markit shall not have any liability, duty or obligation for or relating to the content or information ("data") contained herein, any errors, inaccuracies, omission or delays in the data, or for any actions taken in reliance thereon. In no event shall Markit be liable for any special, incidental, consequential damages, arising out of the use of the data. Markit is a trademark owned by the Markit group.

This report does not constitute nor shall it be construed as an offer by Markit to buy or sell any particular security, financial instrument or financial service. The analysis provided in this report is of a general and impersonal nature. This report shall not be construed as providing investment advice that is adapted to or appropriate for any particular investment strategy or portfolio. This report does not and shall not be construed as providing any recommendations as to whether it is appropriate for any person or entity to "buy", "sell" or "hold" a particular investment.